Linda Griffith received her BS in from Georgia Tech (1982) and her PhD from UC Berkeley (1988), both in Chemical Engineering. She is currently the School of Engineering Professor of Teaching Innovation in Biological Engineering at the Massachusetts Institute of Technology, where she also directs the Center for Gynepathology Research. She has commercialized several tissue engineering and microphysiological systems platform technologies, including 3DPrinting for bone regeneration and the Liverchip, and is a co-founder of Lumicell, which received FDA approval in 2024 for technology to detect tumor margins intraoperatively. She is leading the NIH Novel Alternative Methods (NAMs) Technology Development Center for Women’s Health, focusing on endometriosis drug development and sex-specific organs on chips. She is a member of the National Academy of Engineering, the National Academy of Medicine, the National Academy of Inventors, the American Academy of Arts and Sciences, a MacArthur Foundation Fellow, and has received numerous other awards from professional societies and from MIT. She has served on the advisory board of the Society for Women’s Health Research and on the advisory committee to the director of the National Institutes of Health (2016-2019). She is a founding member of MIT’s Biological Engineering Department and is recognized at MIT as a MacVicar Fellow, awarded for excellence in undergraduate education.